On Aug. 16, 2021, ADMA Biologics announced that it had received U.S. Food and Drug Administration approval for its ADMA BioCenters plasma collection facility located in Maryville, Tennessee.

This plasma collection facility commenced operations and initiated source plasma collection in the fourth quarter of 2020. This facility is FDA-licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S.